Management of gastroesophageal reflux disease

Drugs of Today

Volumn 39, Issue SUPPL. A, 2003, Pages 15-20

  Stanghellini, Vincenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTACID AGENT; CAFFEINE; CARBAMAZEPINE; DIAZEPAM; DICLOFENAC; DIGOXIN; ESOMEPRAZOLE; GLIBENCLAMIDE; LANSOPRAZOLE; METOPROLOL; NAPROXEN; NIFEDIPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENAZONE; PHENPROCOUMON; PHENYTOIN; PIROXICAM; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS; THEOPHYLLINE; WARFARIN;

ACID SECRETION; COMORBIDITY; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOLERABILITY; FOOD REGURGITATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; QUALITY OF LIFE; RELAPSE; STOMACH SECRETION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-ULCER AGENTS; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS;

EID: 0037237999     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Locke, G.R., Talley, N.J., Weaver, A.L., Zinsmeister, A.R. A new questionnaire for gastroesophageal reflux disease. Mayo Clinic Proceedings 1994, 69: 539-47.
2. Klauser, A., Schindlbeck, N., Muller-Lissner, S. Symptoms of gastro-oesophageal reflux disease. Lancet 1990, 335: 205-8.
3. Carlsson, R., Dent, J., Watts, R. et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998, 10(2): 119-24.
4. Carlsson, R., Dent, J., Bolling-Sternevald, E. et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998, 33 (10): 1023-9.
5. Chiba, N., De Gara, C.J., Wilkinson, J.M., Hunt, R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997, 112(6): 1798-810.
6. Savarino, V., Mela, G.S., Zentilin, P. et al. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 1994, 39(1): 161-8.
7. Koerner, T., Schütze, K., van Leendert, R.J.M. et al. Comparable efficacy of pantoprazole 40 mg vs. omeprazole 40 MUPS mg in patients with GERD II/III. Gut 2002, 51(Suppl. III): A166.
8. Eissele, R., Gatz, G., Hole, U. Pantoprazole 40 mg and esomeprazole 40 mg show equivalent healing rates in patients with GERD. Gut 2002, 51(Suppl. III): A165.
9. Scholten, T., Hole, U., Gatz, G. Pantoprazole 40 mg showed a significantly faster relief of GERD-associated symptoms than esomeprazole 40 mg. Gut 2002, 51 (Suppl. III): A169.
10. Teichtahl, H., Kronborg, I.J., Yeomans, N.D., Robinson, P. Adult asthma and gastro-oesophageal reflux: The effects of omeprazole therapy on asthma. Aust N Z J Med 1996, 26(5): 671-6.
11. Boeree, M.J., Peters, F.T., Postma, D.S., Kleibeuker, J.H. No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. Eur Respir J 1998, 11(5): 1070-4.
12. Kiljander, T.O., Salomaa, E.R., Hietanen, E.K., Terho, E.O. Gastroesophageal reflux in asthmatics: A double-blind, placebo-controlled crossover study with omeprazole. Chest 1999, 116(5): 1257-64.
13. Plein, K., Hotz, J., Wurzer, H., Fumagalli, I., Luhmann, R., Schneider, A. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000, 12(4): 425-32.
14. Escourrou, J., Deprez, P., Saggioro, A., Geldof, H., Fischer, R., Maier, C. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999, 13(11): 1481-91.
15. Lundell, L. Prevention of relapse of reflux oesophagitis after endoscopic healing: The efficacy and safety of omeprazole compared with ranitidine. Digestion 1990, 47(Suppl. 1): 72-5.
16. Bardhan, K.D. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993, 7(Suppl. 1): 13-24.
17. Dent, J., Yeomans, N.D., Mackinnon, M. et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994, 35(5): 590-8.
18. Bardhan, K.D. The role of proton pump inhibitors in the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995, 9(Suppl. 1): 15-25.
19. Gough, A.L., Long, R.G., Cooper, B.T., Fosters, C.S., Garrett, A.D., Langworthy, C.H. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996, 10 (4): 529-39.
20. Sontag, S.J., Kogut, D.G., Fleischmann, R., Campbell, D.R., Richter, J., Haber, M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996, 91(9): 1758-65.
21. Vigneri, S., Termini, R., Leandro, G. et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995, 333(17): 1106-10.
22. Bardhan, K.D. Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today 1999, 35(10): 773-808.
23. Viergutz, S., Culshaw, K., Schlander, M. et al. A comparison of the cost-effectiveness of pantoprazole in treating peptic ulcer disease in 6 European countries. Gastroenterology 1998, 114(4), Part 2: A324.
24. Van Rensburg, C.J., Honiball, P.J., Van Zyl, J.H. et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis - a 2-year follow-up. Aliment Pharmacol Ther 1999, 13(8): 1023-8.
25. Howden, C.W., Reid, J.L. The effect of antacids and metoclopramide on omeprazole absorption and disposition. Br J Clin Pharmacol 1988, 25(6): 779-81.
26. Gerloff, J., Barth, H., Mignot, A., Fuchs, W., Heintze, K. Does the proton pump inhibitor lansoprazole interact with antacids? Arch Pharmacol 1993, 347(Suppl.): R31.
27. Yasuda, S., Higashi, S., Murakami, M., Tomono, Y., Kawaguchi, M. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther 1999, 37(5): 249-53.
28. Hartmann, M., Bliesath, H. et al. Lack of influence of antacids on the pharmacokinetics of the new gastric H+/K+H+-ATPase inhibitor pantoprazole. Gastroenterology 1994, Part 2 106(4): A91.
29. Klotz, U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000, 38(3): 243-70.
30. Hartmann, M., Schulz, H.U., Krupp, S. et al. Pantoprazole lacks interaction with the NSAID naproxen in man. Eur J Clin Pharmacol 2000, 56(6-7): A17.
31. Hartmann, M., Bliesath, H., Maier, J. et al. Pantoprazole lacks interaction with the NSAID piroxicam in man. Eur J Clin Pharmacol 2000, 56(6-7): A16.
32. Lorf, T., Ramadori, G., Ringe, B., Schwörer, H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol 2000, 56: 439-40.